

Nick J Bansback

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3118577/nick-j-bansback-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

6,268
citations

35
h-index

76
g-index

160
ext. papers

7,299
ext. citations

3.5
avg, IF

5.8
L-index

#	Paper	IF	Citations
153	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data.. <i>Cmaj</i> , 2022 , 194, E556-E560	3.5	1
152	Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART. <i>BMC Medical Research Methodology</i> , 2021 , 21, 60	4.7	0
151	Development of an Implementation Strategy for Patient Decision Aids in Rheumatoid Arthritis Through Application of the Behavior Change Wheel. <i>ACR Open Rheumatology</i> , 2021 , 3, 312-323	3.5	2
150	Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study. <i>Rheumatology International</i> , 2021 , 1	3.6	1
149	Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211029966	2	
148	Patient-provider communication about medication cost in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021 , 40, 93-100	3.9	3
147	Respondent Understanding in Discrete Choice Experiments: A Scoping Review. <i>Patient</i> , 2021 , 14, 17-53	3.7	6
146	Patients' Experiences and Priorities for Accessing Gastroenterology Care. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021 , 4, 3-9	0.5	0
145	When does the use of individual patient data in network meta-analysis make a difference? A simulation study. <i>BMC Medical Research Methodology</i> , 2021 , 21, 21	4.7	2
144	Patient preferences to value health outcomes in rheumatology clinical trials: Report from the OMERACT special interest group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 919-924	5.3	4
143	Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients. <i>Patient</i> , 2021 , 1	3.7	1
142	An economic valuation technique identified different inpatient care experience as priorities for older Canadians than a traditional approach. <i>Journal of Clinical Epidemiology</i> , 2021 , 139, 1-11	5.7	
141	Comorbidities Before and After the Diagnosis of Rheumatoid Arthritis: A Matched Longitudinal Study. <i>ACR Open Rheumatology</i> , 2020 , 2, 648-656	3.5	1
140	Patient Preferences and Decisional Needs When Choosing a Treatment Approach for Pregnancy Hypertension: A Stated Preference Study. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 775-779	3.8	4
139	Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration. <i>Medical Care</i> , 2020 , 58, 566-573	3.1	22
138	Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. <i>ACR Open Rheumatology</i> , 2020 , 2, 79-83	3.5	6
137	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. <i>Clinical Rheumatology</i> , 2020 , 39, 2931-2941	3.9	8

136	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020 , 28, 100573	11.3	10
135	Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 829-838	2.4	9
134	Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model. <i>Medical Decision Making</i> , 2020 , 40, 1003-1019	2.5	5
133	Patient-Reported Outcome Measures (PROMs) to Support Adherence to Falls Prevention Clinic Recommendations: A Qualitative Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 2105-2121	2.4	1
132	Implausible States: Prevalence of EQ-5D-5L States in the General Population and Its Effect on Health State Valuation. <i>Medical Decision Making</i> , 2020 , 40, 735-745	2.5	1
131	Patient-Oriented Research from the ISDM 2019 Conference: A Legacy Now More Relevant Than Ever. <i>Patient</i> , 2020 , 13, 649-652	3.7	
130	Validation of a novel diabetic retinopathy utility index using discrete choice experiments. <i>British Journal of Ophthalmology</i> , 2020 , 104, 188-193	5.5	2
129	Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2020 , 47, 176-187	4.1	23
128	Manipulating the 5 Dimensions of the EuroQol Instrument: The Effects on Self-Reporting Actual Health and Valuing Hypothetical Health States. <i>Medical Decision Making</i> , 2019 , 39, 379-392	2.5	5
127	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. <i>PLoS ONE</i> , 2019 , 14, e0216075	3.7	16
126	An individualized patient-reported outcome measure (PROM) based patient decision aid and surgeon report for patients considering total knee arthroplasty: protocol for a pragmatic randomized controlled trial. <i>BMC Musculoskeletal Disorders</i> , 2019 , 20, 89	2.8	12
125	Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients. <i>BMC Neurology</i> , 2019 , 19, 173	3.1	8
124	Support Tools for Preference-Sensitive Decisions in Healthcare: Where Are We? Where Do We Go? How Do We Get There?. <i>Patient</i> , 2019 , 12, 439-443	3.7	4
123	Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI. <i>RMD Open</i> , 2019 , 5, e000872	5.9	3
122	Communicating uncertainty in cancer prognosis: A review of web-based prognostic tools. <i>Patient Education and Counseling</i> , 2019 , 102, 842-849	3.1	6
121	Early cost-effectiveness modeling for better decisions in public research investment of personalized medicine technologies. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 7-19	2.1	5
120	Evaluating Canadian PValues for Drug Coverage Decision Making. <i>Value in Health</i> , 2019 , 22, 362-369	3.3	4
119	Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive study. <i>Thrombosis Research</i> , 2019 , 173, 109-116	8.2	12

118	Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. <i>Addiction</i> , 2018 , 113, 1264-1273	4.6	20
117	The use of routinely collected patient-reported outcome measures in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 357-366	5.3	11
116	Assessing an Interactive Online Tool to Support Parents' Genomic Testing Decisions. <i>Journal of Genetic Counseling</i> , 2018 , 28, 10	2.5	13
115	How Should Discrete Choice Experiments with Duration Choice Sets Be Presented for the Valuation of Health States?. <i>Medical Decision Making</i> , 2018 , 38, 306-318	2.5	6
114	Preferences for New Treatments Diminish in the Face of Ambiguity. <i>Health Economics (United Kingdom)</i> , 2017 , 26, 743-752	2.4	5
113	A Cost-Effectiveness Analysis of Reverse Total Shoulder Arthroplasty versus Hemiarthroplasty for the Management of Complex Proximal Humeral Fractures in the Elderly. <i>Value in Health</i> , 2017 , 20, 404-411	4.3	22
112	Communicating Uncertainty in Benefits and Harms: A Review of Patient Decision Support Interventions. <i>Patient</i> , 2017 , 10, 311-319	3.7	13
111	Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2017 , 26, 1483-1492	3.7	4
110	Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial. <i>Osteoarthritis and Cartilage</i> , 2017 , 25, 1615-1622	6.2	22
109	Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment. <i>Value in Health</i> , 2017 , 20, 969-975	3.3	15
108	Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , 2017 , 167, 8-16	8	29
107	Moving from outcomes to values to deliver high-quality health care-A new checklist for valuation studies. <i>Journal of Clinical Epidemiology</i> , 2017 , 83, 3-5	5.7	
106	Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences. <i>Medical Decision Making</i> , 2017 , 37, 285-297	2.5	22
105	OMERACT Quality-adjusted Life-years (QALY) Working Group: Do Current QALY Measures Capture What Matters to Patients?. <i>Journal of Rheumatology</i> , 2017 , 44, 1899-1903	4.1	8
104	Do Women Have a Choice? Care Providers' and Decision Makers' Perspectives on Barriers to Access of Health Services for Birth after a Previous Cesarean. <i>Birth</i> , 2017 , 44, 153-160	3.1	19
103	The burden of nonadherence among adults with asthma: a role for shared decision-making. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017 , 72, 705-712	9.3	16
102	Recognizing difficult trade-offs: values and treatment preferences for end-of-life care in a multi-site survey of adult patients in family practices. <i>BMC Medical Informatics and Decision Making</i> , 2017 , 17, 164	3.6	7
101	Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates. <i>Cost Effectiveness and Resource Allocation</i> , 2017 , 15, 20	2.4	2

100	Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. <i>MDM Policy and Practice</i> , 2017 , 2, 23814683-17716440		
99	Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. <i>BMJ Open</i> , 2017 , 7, e014719	3	35
98	Do Biologic Therapies for Rheumatoid Arthritis Offset Treatment-Related Resource Utilization and Cost? A Review of the Literature and an Instrumental Variable Analysis. <i>Current Rheumatology Reports</i> , 2017 , 19, 54	4.9	9
97	Adherence to Antitumor Necrosis Factor Use Recommendations in Spondyloarthritis: Measurement and Effect in the DESIR Cohort. <i>Journal of Rheumatology</i> , 2017 , 44, 1436-1444	4.1	0
96	Seeking control in the midst of uncertainty: Women's experiences of choosing mode of birth after caesarean. <i>Women and Birth</i> , 2017 , 30, 129-136	3.3	22
95	Testing and treatment for obstructive sleep apnea in Canada: funding models must change. <i>Cmaj</i> , 2017 , 189, E1524-E1528	3.5	13
94	Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. <i>Current Rheumatology Reports</i> , 2016 , 18, 51	4.9	30
93	Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016 , 68, 1866-1873	4.7	44
92	Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study. <i>RMD Open</i> , 2016 , 2, e000222	5.9	2
91	A measurement framework for adherence in patient decision aid trials applied in a systematic review subanalysis. <i>Journal of Clinical Epidemiology</i> , 2016 , 77, 15-23	5.7	12
90	DECIDE: a Decision Support Tool to Facilitate Parents' Choices Regarding Genome-Wide Sequencing. <i>Journal of Genetic Counseling</i> , 2016 , 25, 1298-1308	2.5	27
89	Exclusion Criteria in National Health State Valuation Studies: A Systematic Review. <i>Medical Decision Making</i> , 2016 , 36, 798-810	2.5	22
88	Does Introducing Imprecision around Probabilities for Benefit and Harm Influence the Way People Value Treatments?. <i>Medical Decision Making</i> , 2016 , 36, 490-502	2.5	17
87	Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review. <i>Patient Education and Counseling</i> , 2016 , 99, 491-500	3.1	21
86	Use of network meta-analysis in clinical guidelines. <i>Bulletin of the World Health Organization</i> , 2016 , 94, 782-784	8.2	67
85	Bar Code Medication Administration Technology: A Systematic Review of Impact on Patient Safety When Used with Computerized Prescriber Order Entry and Automated Dispensing Devices. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 394-402	0.5	21
84	Attitude to health risk in the Canadian population: a cross-sectional survey. <i>CMAJ Open</i> , 2016 , 4, E284-912.5	2.5	6
83	A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. <i>Medical Care</i> , 2016 , 54, 98-105	3.1	188

82	Development and pilot testing of a tool to calculate parental and societal costs of raising a child with intellectual disability. <i>Journal of Intellectual and Developmental Disability</i> , 2016 , 41, 11-20	1.9	5
81	Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort. <i>RMD Open</i> , 2016 , 2, e000230	5.9	8
80	Development of a patient decision aid prototype for adults with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2016 , 20, 653-61	3.1	12
79	Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. <i>Quality of Life Research</i> , 2016 , 25, 1679-85	3.7	18
78	How different are composite and traditional TTO valuations of severe EQ-5D-5L states?. <i>Quality of Life Research</i> , 2016 , 25, 2101-8	3.7	3
77	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. <i>Lancet HIV,the</i> , 2016 , 3, e510-e520	7.8	109
76	Improving patient-centred care for rheumatoid arthritis. <i>Cmaj</i> , 2016 , 188, 999-1000	3.5	
75	Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. <i>Patient</i> , 2015 , 8, 93-101	3.7	14
74	Physician attitudes toward shared decision making: A systematic review. <i>Patient Education and Counseling</i> , 2015 , 98, 1046-57	3.1	135
73	Exploring the Potential Cost-Effectiveness of Patient Decision Aids for Use in Adults with Obstructive Sleep Apnea: A Case Study. <i>Medical Decision Making</i> , 2015 , 35, 671-82	2.5	7
72	How important is mode of administration in treatments for rheumatic diseases and related conditions?. <i>Current Rheumatology Reports</i> , 2015 , 17, 514	4.9	5
71	Surgical assessment: measuring unobserved health. <i>BMC Surgery</i> , 2015 , 15, 4	2.3	0
70	Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. <i>Rheumatology</i> , 2015 , 54, 1816-25	3.9	28
69	Making smart investment decisions in clinical research. <i>Trials</i> , 2015 , 16, 590	2.8	2
68	The effect of OSA on work disability and work-related injuries. <i>Chest</i> , 2015 , 147, 1422-1428	5.3	39
67	Projecting the direct cost burden of osteoarthritis in Canada using a microsimulation model. <i>Osteoarthritis and Cartilage</i> , 2015 , 23, 1654-63	6.2	43
66	Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study. <i>RMD Open</i> , 2015 , 1, e000042	5.9	8
65	Assessing adherence with phototherapy protocols. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 1259-61	4.5	9

64	Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision application) for nudging patients towards high quality decisions. <i>BMC Medical Informatics and Decision Making</i> , 2014 , 14, 62	3.6	14
63	Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers. <i>Vaccine</i> , 2014 , 32, 677-84	4.1	4
62	Exploiting order effects to improve the quality of decisions. <i>Patient Education and Counseling</i> , 2014 , 96, 197-203	3.1	9
61	Testing a discrete choice experiment including duration to value health states for large descriptive systems: addressing design and sampling issues. <i>Social Science and Medicine</i> , 2014 , 114, 38-48	5.1	31
60	Decentralized automated dispensing devices: systematic review of clinical and economic impacts in hospitals. <i>Canadian Journal of Hospital Pharmacy</i> , 2014 , 67, 138-48	0.5	31
59	The cost-effectiveness of patient decision aids: A systematic review. <i>Healthcare</i> , 2014 , 2, 251-7	1.8	23
58	Impact of inflammatory bowel disease on disability. <i>Current Gastroenterology Reports</i> , 2014 , 16, 414	5	25
57	Preparatory study for the reevaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014 , 18, vii-xxvi, 1-191	4.4	44
56	Need for speed: an efficient algorithm for calculation of single-parameter expected value of partial perfect information. <i>Value in Health</i> , 2013 , 16, 438-48	3.3	25
55	Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI. <i>Value in Health</i> , 2013 , 16, 104-13	3.3	50
54	Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 64, 382-91	3.1	8
53	Using a discrete choice experiment to estimate health state utility values. <i>Journal of Health Economics</i> , 2012 , 31, 306-18	3.5	154
52	The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012 , 26, 659-76	5.3	9
51	An update on the measurement of productivity losses due to rheumatoid diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012 , 26, 585-97	5.3	7
50	Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. <i>Value in Health</i> , 2012 , 15, 46-54	3.3	42
49	Work disability rates in RA. Results from an inception cohort with 24 years follow-up. <i>Rheumatology</i> , 2012 , 51, 385-92	3.9	30
48	Factors associated with absenteeism, presenteeism and activity impairment in patients in the first years of RA. <i>Rheumatology</i> , 2012 , 51, 375-84	3.9	47
47	Response to Marginal costs of hospital-acquired conditions: information for priority-setting for patient safety programmes and research? Jackson et al., <i>Journal of Health Services Research & Policy</i> 2011;16:141-6. <i>Journal of Health Services Research and Policy</i> , 2012 , 17, 127	2.4	1

46	The effect of direct-to-consumer genetic tests on anticipated affect and health-seeking behaviors: a pilot survey. <i>Genetic Testing and Molecular Biomarkers</i> , 2012 , 16, 1165-71	1.6	8
45	Understanding the side effects of glucocorticoid therapy: shining a light on a drug everyone thinks they know. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1761-4	2.4	21
44	Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. <i>PLoS ONE</i> , 2012 , 7, e31115	3.7	130
43	Multiple treatment comparison meta-analyses: a step forward into complexity. <i>Clinical Epidemiology</i> , 2011 , 3, 193-202	5.9	52
42	The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. <i>BMJ, The</i> , 2011 , 343, d7031	5.9	118
41	Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire. <i>Journal of Occupational and Environmental Medicine</i> , 2011 , 53, 530-6	2	41
40	Measuring and valuing productivity loss due to poor health: A critical review. <i>Social Science and Medicine</i> , 2011 , 72, 185-92	5.1	194
39	Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2011 , 30 Suppl 1, S9-18	3.9	17
38	The Sheffield rheumatoid arthritis health economic model. <i>Rheumatology</i> , 2011 , 50 Suppl 4, iv26-31	3.9	17
37	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011 , 22, 65-74	2.8	30
36	Valuing health for clinical and economic decisions: directions relevant for rheumatologists. <i>Journal of Rheumatology</i> , 2011 , 38, 1770-5	4.1	12
35	Obesity and overweight in Canada: an updated cost-of-illness study. <i>Obesity Reviews</i> , 2010 , 11, 31-40	10.6	138
34	Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R177	5.7	129
33	Development of a population-based microsimulation model of osteoarthritis in Canada. <i>Osteoarthritis and Cartilage</i> , 2010 , 18, 303-11	6.2	27
32	Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 21	3	24
31	Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 631-9	3.1	37
30	Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. <i>Dermatology</i> , 2009 , 219, 209-18	4.4	82
29	The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. <i>BMC Public Health</i> , 2009 , 9, 88	4.1	2115

28	The economics of treatment in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 83-92	5.3	16
27	The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. <i>Quality of Life Research</i> , 2009 , 18, 815-24	3.7	9
26	The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. <i>Quality of Life Research</i> , 2009 , 18, 1195-205	3.7	41
25	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. <i>Pharmaceutical Statistics</i> , 2009 , 8, 150-62	1	7
24	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. <i>Pharmaceutical Statistics</i> , 2009 , 8, 371-89	1	15
23	Economic evaluation of systemic therapies for moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2009 , 160, 1264-72	4	65
22	Why do patients with inflammatory arthritis often score states "worse than death" on the EQ-5D? An Investigation of the EQ-5D classification system. <i>Value in Health</i> , 2009 , 12, 1026-34	3.3	24
21	Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. <i>Pharmacoeconomics</i> , 2009 , 27, 25-37	4.4	22
20	Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. <i>Annals of Internal Medicine</i> , 2009 , 151, 612-21	8	69
19	Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. <i>Canadian Journal of Neurological Sciences</i> , 2009 , 36, 735-9	1	17
18	Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. <i>Pharmacoeconomics</i> , 2008 , 26, 395-408	4.4	24
17	Impact of the recall period on measuring health utilities for acute events. <i>Health Economics (United Kingdom)</i> , 2008 , 17, 1413-9	2.4	11
16	Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. <i>Arthritis and Rheumatism</i> , 2008 , 58, 939-46		70
15	Health state utility values: a description of their development and application for rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1018-26		18
14	The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. <i>Journal of Rheumatology</i> , 2008 , 35, 592-602	4.1	51
13	Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1729-36	4.1	20
12	Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 963-71		63
11	Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. <i>Statistics in Medicine</i> , 2007 , 26, 1237-54	2.3	110

10	Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. <i>Eye</i> , 2007 , 21, 1455-63	4.4	24
9	Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. <i>Quality of Life Research</i> , 2007 , 16, 533-43	3.7	62
8	Cost-effectiveness of tumor necrosis factor-alpha antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007 , 7, 155-69	2.2	2
7	Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1178-83	4.1	5
6	Cost-effectiveness of surgery plus radiotherapy versus radiotherapy alone for metastatic epidural spinal cord compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 1212-8	4	72
5	A prognostic model for functional outcome in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006 , 33, 1503-10	4.1	11
4	Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 995-1002	2.4	82
3	An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists. <i>Drugs</i> , 2005 , 65, 473-96	12.1	52
2	The impact of age-related macular degeneration on health status utility values. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 4016-23		112
1	A pharmacoeconomic review of adalimumab in the treatment of rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005 , 5, 519-29	2.2	4